Roche Investor Update: Anti-Cancer Agent “Perjeta®” Approved for HER2-positive Inoperable or Recurrent Breast Cancer Montag, 01. Juli 2013 - 07:16

Anti-Cancer Agent “Perjeta®”
Approved for HER2-positive Inoperable or Recurrent Breast Cancer  

Dear Investor,  

Please find attached a press release by Chugai:

 http://www.roche.com/inv-update-2013-07-01a-annex.pdf  

Do not hesitate to contact us for any further questions.  

With best regards, 

     Roche Investor Relations      

              Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail:  karl.mahler@roche.com  

Dr. Sabine Borngräber 
Phone: +41 61 68-88027   
e-mail:  sabine.borngraeber@roche.com  

Luís Correia Ph.D.
Phone: +41 61 68-75284
e-mail: luis.correia@roche.com  

Tamer Farhan Ph.D.
Phone: +41 61 68-82552
e-mail: tamer.farhan@roche.com  

Dr. Nina Mojas 
Phone: +41 61 68-71300   
e-mail:  nina.mojas@roche.com  

Elhan Webb, CFA
Phone: +41 61 68-89630   
e-mail:  elhan.webb@roche.com  

Investor Relations North America  

Thomas Kudsk Larsen
Phone: +1 650 467 2016
e-mail: larsen.thomas@gene.com  

Nina Goworek
Phone: +1 650 467 8737
e-mail: goworek.nina@gene.com  

Ekaterine Kortkhonjia Ph.D.
Phone: +1 650 467 5873
e-mail: kortkhonjia.ekaterine@gene.com